Lesha Bank LLC (QSE:QFBQ)
Qatar · Delayed Price · Currency is QAR 1.910
+0.028 (1.49%)
Aug 13, 2025, 1:12 PM AST
ASLAN Pharmaceuticals Income Statement
Financials in millions QAR. Fiscal year is January - December.
Millions QAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 81.39 | 60.69 | 60.94 | 64.68 | 31.5 | 16.28 | Upgrade |
Other Revenue | 199.8 | 178.01 | 102.45 | 21.87 | 189.12 | -64.36 | Upgrade |
Revenue | 281.19 | 238.71 | 163.38 | 86.55 | 220.62 | -48.08 | Upgrade |
Revenue Growth (YoY) | 61.52% | 46.11% | 88.77% | -60.77% | - | - | Upgrade |
Cost of Revenue | 10.92 | 8.25 | 1.84 | -61.38 | 7.37 | 59.42 | Upgrade |
Gross Profit | 270.27 | 230.46 | 161.54 | 147.93 | 213.25 | -107.5 | Upgrade |
Selling, General & Admin | 81.08 | 75.56 | 66.08 | 59.7 | 56.99 | 57.82 | Upgrade |
Other Operating Expenses | 23.86 | 30.59 | -3.15 | 14.35 | 7.19 | 12.71 | Upgrade |
Operating Expenses | 112.79 | 113.31 | 69.06 | 79.22 | 67.45 | 74.69 | Upgrade |
Operating Income | 157.48 | 117.15 | 92.49 | 68.71 | 145.8 | -182.19 | Upgrade |
Interest Expense | - | - | -0.2 | -5.91 | -5.61 | - | Upgrade |
Currency Exchange Gain (Loss) | 12.07 | 5.57 | 7.67 | 9.47 | -2.51 | -0.52 | Upgrade |
EBT Excluding Unusual Items | 169.55 | 122.72 | 99.96 | 72.26 | 137.68 | -182.71 | Upgrade |
Gain (Loss) on Sale of Investments | -0.68 | 2.14 | 2.71 | 9.43 | -12.07 | -9.82 | Upgrade |
Gain (Loss) on Sale of Assets | -20.31 | 0.91 | - | - | - | - | Upgrade |
Asset Writedown | -6.4 | -6.4 | - | -1 | -2.8 | -18.86 | Upgrade |
Pretax Income | 142.16 | 119.37 | 102.66 | 80.69 | 122.81 | -211.4 | Upgrade |
Earnings From Continuing Operations | 142.16 | 119.37 | 102.66 | 80.69 | 122.81 | -211.4 | Upgrade |
Earnings From Discontinued Operations | - | - | -6.17 | 3.8 | -58 | -43.95 | Upgrade |
Net Income to Company | 142.16 | 119.37 | 96.49 | 84.48 | 64.81 | -255.35 | Upgrade |
Minority Interest in Earnings | 14.31 | 8.8 | -2.1 | -9.01 | 35.56 | 28.64 | Upgrade |
Net Income | 156.47 | 128.17 | 94.39 | 75.47 | 100.37 | -226.71 | Upgrade |
Net Income to Common | 156.47 | 128.17 | 94.39 | 75.47 | 100.37 | -226.71 | Upgrade |
Net Income Growth | 50.74% | 35.78% | 25.07% | -24.81% | - | - | Upgrade |
Shares Outstanding (Basic) | 1,120 | 1,120 | 1,120 | 970 | 700 | 700 | Upgrade |
Shares Outstanding (Diluted) | 1,120 | 1,120 | 1,120 | 970 | 700 | 700 | Upgrade |
Shares Change (YoY) | - | - | 15.44% | 38.60% | - | - | Upgrade |
EPS (Basic) | 0.14 | 0.11 | 0.08 | 0.08 | 0.14 | -0.32 | Upgrade |
EPS (Diluted) | 0.14 | 0.11 | 0.08 | 0.08 | 0.14 | -0.32 | Upgrade |
EPS Growth | 50.75% | 35.78% | 8.34% | -45.75% | - | - | Upgrade |
Free Cash Flow | 204.28 | 35.87 | 59.01 | 251 | 438.65 | -200.72 | Upgrade |
Free Cash Flow Per Share | 0.18 | 0.03 | 0.05 | 0.26 | 0.63 | -0.29 | Upgrade |
Dividend Per Share | 0.050 | 0.050 | - | - | - | - | Upgrade |
Gross Margin | 96.12% | 96.54% | 98.87% | 170.91% | 96.66% | - | Upgrade |
Operating Margin | 56.01% | 49.08% | 56.61% | 79.38% | 66.09% | - | Upgrade |
Profit Margin | 55.65% | 53.69% | 57.77% | 87.20% | 45.50% | - | Upgrade |
Free Cash Flow Margin | 72.65% | 15.03% | 36.12% | 290.00% | 198.83% | - | Upgrade |
EBITDA | 161.54 | 120.51 | 95.77 | 70.08 | 146.15 | -180.56 | Upgrade |
EBITDA Margin | 57.45% | 50.48% | 58.61% | 80.97% | 66.25% | - | Upgrade |
D&A For EBITDA | 4.06 | 3.36 | 3.28 | 1.38 | 0.35 | 1.63 | Upgrade |
EBIT | 157.48 | 117.15 | 92.49 | 68.71 | 145.8 | -182.19 | Upgrade |
EBIT Margin | 56.01% | 49.08% | 56.61% | 79.38% | 66.09% | - | Upgrade |
Revenue as Reported | 406.61 | 384.64 | 288.03 | 115.64 | 226.71 | -42.77 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.